Excellent Phase III results for Vertex’s new cystic fibrosis therapy

Boston, US-based Vertex Pharmaceuticals today has announced extremely positive results from two Phase III clinical trials assessing VX-659 on patients with cystic fibrosis. The results show that patients treated with VX-659 have lung functionality improved by 14% and good therapy tolerance. Analysts believe that these results will probably lead to a fast FDA approval. Because of this, Vertex’s shares have had a 4.5% upsurge (Nasdaq), taking the group’s capitalization to $44bn.

(Source: Vertex)